Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
Université de Montréal
$27,000.00
Defining mechanisms regulating MYC protein stability
FY 2025-26
Summary
MYC is an oncogene that amplifies the effects of SCL and LMO1/2 in T-cell acute lymphoblastic leukemia (T-ALL). Together, these proteins reprogram thymocytes into pre-leukemic stem cells (pre-LSCs), which resist current therapies and drive relapse. Understanding MYC degradation pathways is therefore critical for developing new treatments targeting pre-LSCs. While the T58/S62 MYC degron has been well studied, the T244/T248 degron requires further investigation. This project aims to identify the kinase acting on MYC T244 and discover pre-LSC inhibitors that act by destabilizing MYC protein. First, a high-throughput screen will be conducted using MYC WT and T244A constructs to uncover kinase inhibitors specific to the T244 site. MYC stability will be quantified using the GPS (global protein stability) method, a fluorescence-based assay optimized in the Hoang lab. The kinase identity will then be validated through CRISPR knock-out. The GPS assay will also assess which pre-LSC inhibitors identified in an existing small-molecule screen act through MYC destabilization. Results will be confirmed using cycloheximide chase assays. Importantly, genetic evidence indicates that pre-LSCs rely on the NOTCH1–MYC axis, so inhibitors that destabilize MYC protein are expected to selectively target MYC-addicted pre-LSCs while sparing MYC-resilient healthy hematopoietic stem cells. Overall, this project will refine our understanding of MYC degradation via the ubiquitin–proteasome pathway and support the development of targeted therapies against drug-resilient pre-LSCs. These advances have the potential to reduce relapse in T-ALL and improve outcomes. Moreover, because MYC is implicated in many cancers, elucidating its regulatory mechanisms remains essential for progress in cancer research.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572559
Name
St-Aubin Mathilde
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining mechanisms regulating MYC protein stability
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Global Protein Stability (Gps) Assay; Kinase Inhibitors; Leukemic Stem Cell Inhibition; Myc; Notch1; Pre-Leukemic Stem Cells; Protein Stability; Relapse; T-Cell Acute Lymphoblastic Leukemia; Ubiquitin-Proteasome
Abstract
MYC is an oncogene that amplifies the effects of SCL and LMO1/2 in T-cell acute lymphoblastic leukemia (T-ALL). Together, these proteins reprogram thymocytes into pre-leukemic stem cells (pre-LSCs), which resist current therapies and drive relapse. Understanding MYC degradation pathways is therefore critical for developing new treatments targeting pre-LSCs. While the T58/S62 MYC degron has been well studied, the T244/T248 degron requires further investigation. This project aims to identify the kinase acting on MYC T244 and discover pre-LSC inhibitors that act by destabilizing MYC protein. First, a high-throughput screen will be conducted using MYC WT and T244A constructs to uncover kinase inhibitors specific to the T244 site. MYC stability will be quantified using the GPS (global protein stability) method, a fluorescence-based assay optimized in the Hoang lab. The kinase identity will then be validated through CRISPR knock-out. The GPS assay will also assess which pre-LSC inhibitors identified in an existing small-molecule screen act through MYC destabilization. Results will be confirmed using cycloheximide chase assays. Importantly, genetic evidence indicates that pre-LSCs rely on the NOTCH1–MYC axis, so inhibitors that destabilize MYC protein are expected to selectively target MYC-addicted pre-LSCs while sparing MYC-resilient healthy hematopoietic stem cells. Overall, this project will refine our understanding of MYC degradation via the ubiquitin–proteasome pathway and support the development of targeted therapies against drug-resilient pre-LSCs. These advances have the potential to reduce relapse in T-ALL and improve outcomes. Moreover, because MYC is implicated in many cancers, elucidating its regulatory mechanisms remains essential for progress in cancer research.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
St-Aubin, Mathilde
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~